molecular
diagnosi
respiratori
infect
perform
use
differ
commerci
multiplexbas
pcr
kit
whose
perform
previous
compar
individu
convent
techniqu
studi
compar
practic
diagnost
perform
six
cemark
kit
avail
french
market
includ
detect
virus
atyp
bacteria
pathofind
seegen
compani
detect
virus
abbott
genomica
qiagen
seegen
compani
respect
sensit
specif
accuraci
agreement
multiplex
techniqu
calcul
comparison
commerci
duplex
pcr
test
use
gold
standard
eightyeight
respiratori
specimen
pathogen
n
singl
infect
n
coinfect
n
select
cover
virus
group
virus
atyp
bacteria
sampl
extract
use
nuclisensh
easymag
tm
instrument
overal
sensit
rang
virus
test
bacteria
overal
specif
excel
pathogen
test
kit
overal
agreement
refer
test
strong
virus
kappa
test
moder
bacteria
extract
step
handson
time
vari
min
complet
result
avail
h
spectrum
test
agent
technolog
use
reveal
pcr
product
well
laboratori
organ
determin
select
kit
global
burden
acut
respiratori
infect
ari
remain
huge
problem
public
health
develop
countri
number
viral
respiratori
episod
per
year
estim
children
school
age
versu
age
ari
repres
caus
hospit
admiss
categori
patient
wide
rang
pathogen
involv
ari
includ
bacteria
virus
diagnosi
ari
reli
clinic
examin
radiolog
explor
biolog
nonspecif
inflammatori
test
includ
level
protein
c
reactiv
procalcitonin
identif
caus
agent
often
omit
limit
pathogen
easi
detect
rapid
antigen
direct
test
influenza
virus
respiratori
syncyti
viru
rsv
respiratori
specimen
streptococcu
pneumonia
legionella
pneumophila
urin
specimen
howev
distinct
viral
bacteri
infect
often
imposs
use
nonmicrobiolog
criteria
need
precis
rapid
identif
caus
agent
ari
review
recent
main
advantag
strategi
better
use
antimicrobi
includ
antivir
drug
antibiot
thu
limit
develop
bacteri
resist
ii
reduct
unnecessari
paraclin
explor
durat
hospit
iii
rapid
implement
isol
measur
necessari
thu
limit
risk
nosocomi
transmiss
iv
collect
real
time
new
epidemiolog
data
season
spread
pathogen
v
identif
simultan
success
infect
may
justifi
specif
intervent
explain
sever
clinic
pictur
detect
agent
genom
respons
respiratori
infect
revolution
recent
advanc
field
nucleic
acid
amplif
test
notabl
multiplex
pcr
addit
excel
sensit
much
superior
convent
techniqu
techniqu
allow
simultan
detect
wide
rang
pathogen
mostli
virus
also
atyp
bacteria
includ
mycoplasma
pneumonia
chlamydophila
pneumonia
l
pneumophila
bordetella
pertussi
shorttim
return
result
clinician
object
present
studi
evalu
technic
perform
six
commerci
kit
base
multiplex
pcr
avail
european
market
begin
diagnosi
respiratori
infect
kit
compar
combin
biplex
pcr
test
use
gold
standard
panel
respiratori
secret
select
content
variou
infecti
agent
perform
kit
detect
differ
respiratori
pathogen
includ
sensit
specif
accuraci
agreement
evalu
agent
technic
properti
also
taken
consider
global
kit
whose
commerci
develop
still
pursu
shown
conveni
routin
use
clinic
laboratori
set
six
kit
base
multiplex
detect
respiratori
virus
atyp
bacteria
avail
french
market
test
use
recommend
manufactur
technolog
depict
figur
letter
f
use
design
kit
follow
section
kit
correspond
respifinderh
smart
pathofind
maastricht
netherland
revers
transcript
preamplif
step
perform
geneamph
pcr
system
appli
biosystem
hybrid
ligat
detect
step
system
roch
appli
scienc
kit
b
correspond
seeplexh
onestep
ace
detect
pneumobact
ace
detect
seegen
inc
seoul
south
korea
geneamph
pcr
system
appli
biosystem
use
amplif
size
pcr
product
read
tapest
electrophoresi
use
screentap
kit
c
correspond
magicplex
rv
panel
realtim
test
seegen
inc
amplif
perform
use
geneamph
pcr
system
appli
biosystem
detect
pcr
product
done
appli
biosystem
kit
correspond
clarth
pneumovir
genomica
madrid
spain
amplif
perform
geneamph
pcr
system
appli
biosystem
hybrid
pcr
product
array
read
use
clinic
array
system
car
genomica
kit
e
correspond
xtagh
respiratori
viral
panel
fast
abbott
rungi
franc
kit
f
resplex
ii
panel
qiagen
hilden
germani
two
kit
amplif
perform
geneamph
pcr
system
appli
biosystem
detect
pcr
product
luminex
platform
bioplex
biorad
test
use
gold
standard
evalu
six
kit
describ
correspond
combin
duplex
respiratori
multi
well
system
rgene
tm
influenza
ab
rsv
hmpv
rhino
evcc
adhbov
chlamyco
pneumo
hcovhpiv
bordetella
commerci
marci
letoil
franc
realtim
pcr
reaction
perform
appli
biosystem
virus
andor
bacteria
could
detect
kit
mention
list
tabl
order
constitut
repres
panel
specimen
contain
wide
rang
respiratori
pathogen
virus
atyp
bacteria
test
evalu
kit
respiratori
sampl
univers
hospit
caen
univers
hospit
saintetienn
franc
one
half
nasal
swab
one
half
respiratori
secret
select
sp
fg
jd
av
studi
viral
bacteri
pathogen
routin
detect
immunofluoresc
assay
respiratori
syncyti
virus
influenza
virus
parainfluenza
virus
adenovirus
metapneumovirus
saintetienn
molecular
method
homebrew
method
influenza
saintetienn
chlamyleg
kit
argen
atyp
bacteria
saintetienn
homebrew
molecular
method
virus
rhinovirusesenterovirus
adenovirus
bocaviru
coronavirus
parainfluenza
virus
metapneumovirus
caen
criteria
select
presenc
clinic
ari
ii
detect
respiratori
pathogen
routin
test
describ
except
specimen
test
initi
neg
iii
volum
sampl
least
ml
studi
conduct
residu
clinic
specimen
store
reason
inform
consent
requir
patient
howev
studi
submit
approv
local
ethic
committe
univers
hospit
saintetienn
result
screen
test
taken
consider
select
repres
divers
respiratori
pathogen
final
analysi
mani
specimen
found
posit
addit
pathogen
refer
preliminari
screen
sampl
fraction
blindli
ml
tube
contain
ml
specimen
frozen
techniqu
test
one
aliquot
specimen
thaw
nucleic
acid
extract
use
nuclisensh
easymag
tm
presenc
ml
proteinas
k
mgml
intern
control
avail
recommend
manufactur
figur
nucleic
acid
elut
volum
ml
kit
ml
kit
b
c
f
ml
kit
e
refer
method
ml
sampl
elut
ml
revers
transcript
pcr
reaction
perform
immedi
extract
extract
conserv
investig
necessari
signal
detect
consid
posit
interpret
result
obtain
kit
valid
acknowledg
correspond
supplier
respect
sensit
specif
accuraci
agreement
evalu
cohen
kappa
coeffici
test
kit
calcul
refer
perform
argen
duplex
test
use
gold
standard
follow
test
sampl
refer
method
number
pathogen
consid
present
panel
depict
tabl
pathogen
except
influenza
viru
frequent
associ
least
anoth
pathogen
perform
kit
summar
tabl
virus
tabl
bacteria
overal
sensit
rang
virus
tabl
kit
b
f
exhibit
poorest
sensit
viral
agent
test
found
sensit
influenza
virus
except
kit
e
influenza
b
viru
rsv
metapneumoviru
parainfluenza
virus
less
sensit
gold
standard
rhinovirusesenterovirus
adenovirus
bocaviru
panel
composit
coronavirus
tabl
explain
low
sensit
kit
b
detect
type
pathogen
tabl
regard
bacteria
sensit
kit
b
satisfi
mycoplasma
pneumonia
chlamydophila
pneumonia
close
bordetella
pertussi
tabl
overal
specif
kit
excel
pathogen
lowest
specif
observ
rhinovirus
enterovirus
kit
c
e
respect
global
accuraci
adequ
even
lower
valu
observ
rhinovirusesenterovirus
adenovirus
cohen
kappa
coeffici
reflect
agreement
gold
standard
global
strong
virus
tabl
moder
bacteria
tabl
criteria
evalu
technic
workflow
characterist
kit
depict
tabl
ten
sampl
analyz
one
run
extract
step
control
addit
intern
control
kit
ten
ml
extract
need
analysi
extract
step
handson
time
vari
min
depend
number
reaction
tube
open
avail
readytous
reagent
number
mastermix
signal
interpret
driven
use
dedic
softwar
three
kit
run
durat
vari
h
knowledg
studi
first
compar
commerci
multiplex
pcr
techniqu
detect
tabl
perform
kit
evalu
studi
panel
atyp
bacteria
refer
combin
duplex
pcr
test
use
gold
standard
respiratori
pathogen
five
kit
b
e
f
previous
evalu
versu
convent
techniqu
homebrew
pcr
commerci
multiplex
kit
howev
none
studi
compar
commerci
techniqu
simultan
noteworthi
kit
test
studi
constitut
exhaust
panel
techniqu
present
commerci
world
market
repres
avail
europ
begin
present
comparison
includ
two
multiplex
techniqu
b
abl
detect
respiratori
virus
togeth
atyp
bacteria
molecular
diagnosi
bacteria
often
perform
use
homebrew
method
commerci
techniqu
evalu
compar
simultan
detect
atyp
bacteria
virus
repres
great
advantag
term
clinic
manag
inde
case
posit
result
atyp
bacterium
rapid
treatment
adapt
antimicrobi
drug
propos
contrast
inform
lack
risk
prescrib
treatment
especi
specimen
also
found
posit
one
sever
virus
rather
common
situat
present
panel
opposit
case
absenc
atyp
bacteria
togeth
neg
convent
bacteri
cultur
would
allow
spare
useless
antibiot
treatment
consequ
emerg
bacteri
resist
studi
exhibit
limit
gold
standard
avail
pathogen
test
studi
even
molecular
techniqu
global
consid
sensit
difficult
identifi
precis
method
refer
given
pathogen
famili
pathogen
addit
sensit
may
vari
test
adapt
whole
famili
adenovirus
rhinovirusesenterovirus
parainfluenza
virus
specif
singl
type
despit
difficulti
strategi
consist
combin
duplex
real
time
pcr
method
taken
gold
standard
present
studi
actual
reduc
primer
competit
due
combin
biplex
amplif
togeth
higher
volum
extract
sampl
indic
good
sensit
low
number
strain
pathogen
ie
cpneumophila
absenc
other
notabl
parainfluenza
viru
type
lpneumophila
constitut
addit
limit
studi
accur
comparison
anoth
difficulti
compar
differ
kit
reli
level
differenti
test
pathogen
vari
greatli
manufactur
anoth
instanc
kit
abl
detect
coronavirus
parainfluenza
virus
type
speci
level
wherea
other
consid
genu
level
adenovirus
rhino
enterovirus
kit
use
genusspecif
target
note
none
kit
abl
detect
parechoviru
despit
recent
involv
genu
picornavirida
respiratori
infect
term
sensit
kit
b
f
exhibit
lowest
result
accord
previou
evalu
comparison
molecular
test
despit
good
perform
refer
convent
techniqu
pioneer
technolog
either
stop
improv
new
gener
kit
exemplifi
kit
c
repres
version
kit
b
exhibit
best
sensit
test
virus
fact
panel
includ
larg
number
multipl
infect
could
explain
miss
result
multiplex
pcr
assay
test
studi
inde
technolog
favor
primer
competit
notabl
pathogen
exhibit
lower
load
specimen
observ
may
explain
overal
low
sensit
observ
coronavirus
adenovirus
bocavirus
concern
kit
accord
previou
result
homebrew
pcr
techniqu
exhibit
correct
sensit
except
coronaviru
essenti
detect
type
kit
e
extens
test
good
analyt
perform
perform
observ
studi
confirm
result
despit
defect
notabl
adenoviru
report
perform
kit
satisfactori
accord
previou
evalu
poor
result
obtain
b
pertussi
led
chang
target
use
detect
bacterium
regard
technic
workflow
characterist
kit
import
favor
techniqu
readytous
reagent
littl
number
reaction
tube
open
limit
number
pipet
order
reduc
risk
mistak
reagent
handl
crosscontamin
sever
compani
trend
mark
featur
drive
evolut
kit
presenc
intern
control
possibl
cellular
control
also
recommend
check
valid
neg
result
final
although
result
techniqu
avail
less
hour
run
durat
vari
significantli
techniqu
anoth
studi
would
need
evalu
consequ
differ
clinic
point
view
conclus
present
studi
constitut
overview
multiplex
techniqu
avail
european
market
diagnosi
respiratori
infect
perform
global
satisfactori
least
still
commerciallyavail
basi
present
evalu
spectrum
detect
pathogen
advantag
techniqu
detect
also
atyp
bacteria
technolog
use
pcr
product
revel
laboratori
organ
appear
determin
featur
select
kit
studi
need
evalu
costbenefit
techniqu
clinic
manag
respiratori
infect
